Carmot is currently conducting a multi-center, randomized, placebo-controlled Phase 2 clinical trial of CT-868 in participants with overweight/obesity and T1D to assess efficacy, safety, tolerability, and pharmacokinetics
Eligibility is always a doctors decision after blood tests this is not a self-diagnosis tool
or BMI 27 kg/m with at least one indicator of increased cardiovascular risk (e.g., coronary heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference), or another obesity-related medical condition (e.g., sleep apnea)
Missing data for key variables were handled using available case analysis, which included only the participants with complete data for those variables in the analysis
Bioengineered 13 , 89618971 (2022)
CMS checks the request to see if you qualify